Titration of the recombinant TNFSF15 antibody may be required for optimal performance.
1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. Immunohistochemistry (FFPE): 1-2 μg/mL,Prediluted IHC only format : incubate for 30 min at RT (1)
Restrictions
For Research Use only
Buffer
0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced) and 0.05 % sodium azide
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C,-20 °C
Storage Comment
Store the recombinant TNFSF15 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).
Target
TNFSF15
(Tumor Necrosis Factor (Ligand) Superfamily, Member 15 (TNFSF15))
TNF ligand-related molecule 1 is an anti-angiogenic cytokine that is also called Tumor necrosis factor superfamily, member 15 (TNFSF15) and Vascular endothelial growth inhibitor (VEGI/VEGI192A). This protein is abundantly expressed in endothelial cells, but is not expressed in either B or T cells. The expression of this protein is inducible by TNF and IL-1 alpha. This cytokine is a ligand for receptor TNFRSF25 and decoy receptor TNFRSF21/DR6. It can activate NF-kappaB and MAP kinases, and acts as an autocrine factor to induce apoptosis in endothelial cells. This cytokine is also found to inhibit endothelial cell proliferation, and thus may function as an angiogenesis inhibitor. Reduced expression of TL1A/TNFSF15/VEGI has been reported as a marker of poor prognosis in breast cancer.